new option listings on November 25th » 08:3011/2511/25/20
ABIO, AHCO, DMTK, DRIV, EDOC, EKSO, FAN, GP, KZIA, MSP, QLGN, ROOT, RVMD, TCON
New option listings for…
New option listings for November 25th include ARCA Biopharma (ABIO), AdaptHealth Corporation (Class A Stock) (AHCO), DermTech Inc (DMTK), Global X Autonomous and Electric Vehicles (DRIV), Direxion Daily Industrials Bull 3x Shares (DUSL), Global X E commerce ETF (EBIZ), Global X Telemedicine and Digital Health (EDOC), Ekso Bionics (EKSO), First Trust ISE Global Wind Energy Index Fund (FAN), Fidelity Low Volatility Factor ETF (FDLO), First Trust DJ Global Select Dividend Index Fund (FGD), GreenPower Motor Company Inc (GP), Direxion Daily South Korea Bull 3X Shares (KORU), Kazia Therapeutics Ltd (ADS) (KZIA), Datto Holding Corp (MSP), Qualigen Therapeutics Inc (QLGN), Root Inc (ROOT), Revolution Medicines Inc (RVMD), TRACON Pharmaceuticals (TCON), Direxion Daily Transportation Bull 3x Shares (TPOR), and WisdomTree Cloud Computing Fund (WCLD).
|Over a month ago|
Ekso Bionics announces EGM Builders as first customer to adopt EVO tech » 08:3010/2910/29/20
Ekso Bionics Holdings…
Ekso Bionics Holdings announced that EGM Builders, a self-performing general contractor providing construction services in New Jersey and New York, is the first customer to acquire EVO units. Launched in August 2020, EVO is the Company's latest innovation in exoskeleton technology for industrial use.
|Over a quarter ago|
Ekso Bionics unveils latest assistive exoskeleton for industrial use » 08:4008/2008/20/20
Ekso Bionics unveiled…
Ekso Bionics unveiled EVO, an endurance-boosting assistive upper body exoskeleton that alleviates the burden of repetitive work. Building on the Company's trailblazing EksoVest technology, EVO's innovative design is the next step in the evolution of industrial exoskeletons. Through collaborations with leaders in global manufacturing and construction, Ekso Bionics has accumulated a wealth of in-the-field customer insights that allowed it to reimagine its weight-assist exoskeleton technology. EVO is lighter and more flexible than its predecessor, with an optimized human-machine interface that is cool and comfortable to wear for all-day use, while also maintaining the ruggedness and durability that Ekso is known for. EVO's novel design also incorporates Ekso's new patented low profile, multi-link structure, which tracks the natural movement of the body and allows for an unrestricted range of motion, and a device architecture that is compatible with standard safety harnesses used in elevated work. These advancements in design make EVO the ideal solution for a wide range of industrial, manufacturing, food processing, and construction applications.
Ekso Bionics reports Q2 EPS ($1.88), consensus (55c) » 16:2507/3007/30/20
Reports Q2 revenue $2.3M,…
Reports Q2 revenue $2.3M, consensus $1.62M. We are pleased with our team's strong execution in navigating through an extraordinarily difficult environment," said Jack Peurach, President and Chief Executive Officer of Ekso Bionics. "Through our virtual selling approach, we maintained a strong order pipeline by staying connected with our customer rehabilitation centers and network operators in delivering online service support and training. Operationally, at the start of the COVID-19 pandemic we took immediate actions to adjust our cost structure, enabling us to adapt to the new environment under these challenging market conditions. While the pandemic may impact the near-term outlook for the customers that we serve, we remain flexible both strategically and operationally to create long-term value for patients, customers, and our shareholders."
Ekso Bionics files to sell 874K shares of common stock for holders 17:2507/0207/02/20
Fly Intel: Pre-market Movers » 09:0306/2606/26/20
GPS, ZGNX, AXSM, EKSO, VXRT, BIG, NKE, APOG, DBVT, SOLY, IDEX
Check out this morning's…
Ekso Bionics price target raised to $12 from $8 at H.C. Wainwright » 06:1906/2606/26/20
H.C. Wainwright analyst…
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm's price target on Ekso Bionics to $12 from $8 and reiterates a Buy rating on the shares after the company received 501(k) clearance from the FDA to market its lead product, EksoNR robotic exoskeleton, for the treatment of patients with acquired brain injuries. The analyst believes that the addition of new indication bodes well for a stronger adoption and to treat a broader group of patients.
Ekso Bionics receives FDA clearance to market EksoNR robotic exoskeleton » 08:3706/2506/25/20
Ekso Bionics announced it…
Ekso Bionics announced it has received 501(k) clearance from the U.S. Food and Drug Administration to market its EksoNR robotic exoskeleton for use with patients with acquired brain injury. EksoNR is the first exoskeleton device to receive FDA clearance for rehabilitation use with ABI, significantly expanding the device's indication to a broader group of patients. EksoNR is the next generation device of the most clinically used robotic exoskeleton, and was previously cleared by the FDA for stroke and spinal cord injury rehabilitation in 2016. The device was the first of its kind to receive a stroke indication and is now also the first to receive an ABI indication. EksoNR is cleared by the FDA for stroke, spinal cord injury, and acquired brain injury rehabilitation. The device is also CE-marked and available in Europe.
Ekso Bionics files $75M mixed securities shelf 09:3506/1606/16/20
Ekso Bionics announces closing of $7.89M registered direct offering » 13:3406/1006/10/20
Ekso Bionics Holdings…
Ekso Bionics Holdings announced the closing of its previously announced registered direct offering of 1,747,704 shares of its common stock at a purchase price of $4.5145 per share and the concurrent private placement of warrants to purchase up to 873,852 shares of its common stock issued to the accredited investors in the registered direct offering priced at-the-market under Nasdaq Rules, for aggregate gross proceeds of approximately $7.89M. The warrants are immediately exercisable, have an exercise price of $5.18 per share and a term of five and one-half years from the issuance date. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The company intends to use the net proceeds from the offering for working capital and general corporate purposes.